New insight into the mechanisms associated with the rapid effect of T 3 on AT1R expression

Journal of Molecular Endocrinology

Volumn 49, Issue 1, 2012, Pages 11-20

  Diniz, Gabriela Placoná ^a   Takano, Ana Paula Cremasco ^a   Bruneto, Erika ^a   da Silva, Francemilson Goulart ^a   Nunes, Maria Tereza ^a   Barreto Chaves, Maria Luiza Morais ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; COMPLEMENTARY DNA; LIOTHYRONINE; MESSENGER RNA; UBIQUITINATED PROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART MUSCLE CELL; NONHUMAN; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MICRORNAS; MYOCYTES, CARDIAC; POLYADENYLATION; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; TRIIODOTHYRONINE; UBIQUITINATED PROTEINS; UBIQUITINATION;

EID: 84863524225     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-11-0141     Document Type: Article

References (67)

1. Asahi T, Shimabukuro M, Oshiro Y, Yoshida H & Takasu N 2001 Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats. Thyroid 11 1009-1015. (doi:10.1089/105072501753271680)
2. Barreto-Chaves ML, Heimann A & Krieger JE 2000 Stimulatory effect of dexamethasone on angiotensin-converting enzyme in neonatal rat cardiac myocytes. Brazilian Journal of Medical and Biological Research 33 661-664. (doi:10.1590/S0100-879X2000000600007)
3. Bartel DP 2004 MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 281-297. (doi:10.1016/S0092-8674(04)00045-5)
4. Basset A, Blanc J, Messas E, Hagege A & Elghozi JL 2001 Renin-angiotensin system contribution to cardiac hypertrophy in experimental hyperthyroidism: an echocardiographic study. Journal of Cardiovascular Pharmacology 37 163-172. (doi:10.1097/00005344-200102000-00004)
5. Bernstein P, Peltz SW & Ross J 1989 The poly(A)-poly(A)-binding protein complex is a major determinant of mRNA stability in vitro. Molecular and Cellular Biology 9 659-670.
6. 3 rapidly increases SLC2A4 gene expression and GLUT4 trafficking to the plasma membrane in skeletal muscle of rat and improves glucose homeostasis. Thyroid 22 70-79. (doi:10.1089/thy.2010.0409)
7. Cao HJ, Lin HY, Luidens MK, Davis FB & Davis PJ 2009 Cytoplasmto-nucleus shuttling of thyroid hormone receptor-b1 (Trb1) is directed from a plasma membrane integrin receptor by thyroid hormone. Endocrine Research 34 31-42. (doi:10.3109/07435800903204082)
8. Carneiro-Ramos MS, Diniz GP, Nadu AP, Almeida J, Vieira RL, Santos RA & Barreto-Chaves ML 2010 Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. Basic Research in Cardiology 105 325-335. (doi:10.1007/s00395-010-0089-0)
9. Chattergoon NN, Giraud GD, Louey S, Stork P, Fowden AL & Thornburg KL 2011 Thyroid hormone drives fetal cardiomyocyte maturation. FASEB Journal 26 397-408. (doi:10.1096/fj.10-179895)
10. Cheng SY, Gong QH, Parkison C, Robinson EA, Appella E, Merlino GT & Pastan I 1987 The nucleotide sequence of a human cellular thyroid hormone binding protein present in endoplasmic reticulum. Journal of Biological Chemistry 262 11221-11227.
11. Cordes KR & Srivastava D 2009 MicroRNA regulation of cardiovascular development. Circulation Research 104 724-732. (doi:10.1161/CIRCRESAHA.108.192872)
12. Danzi S & Klein I 2005 Posttranscriptional regulation of myosin heavy chain expression in the heart by triiodothyronine. American Journal of Physiology. Heart and Circulatory Physiology 288 H455 H460. (doi:10.1152/ajpheart.00896.2004)
13. Davis PJ & Davis FB 2002 Nongenomic actions of thyroid hormone on the heart. Thyroid 12 459-466. (doi:10.1089/105072502760143827)
14. Davis PJ, Davis FB & Cody V 2005 Membrane receptors mediating thyroid hormone action. Trends in Endocrinology and Metabolism 16 429-435. (doi:10.1016/j.tem.2005.09.007)
15. Davis PJ, Leonard JL & Davis FB 2008 Mechanisms of nongenomic actions of thyroid hormone. Frontiers in Neuroendocrinology 29 211-218. (doi:10.1016/j.yfrne.2007.09.003)
16. Dillmann W 2009 Cardiac hypertrophy and thyroid hormone signaling. Heart Failure Reviews 15 125-132. (doi:10.1007/s10741-008-9125-7)
17. Diniz GP, Carneiro-Ramos MS & Barreto-Chaves ML 2009 Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy throughtheAkt/GSK-3b/mTORsignalingpathway. Basic Research in Cardiology 104 653-667. (doi:10.1007/s00395-009-0043-1)
18. Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, Cimino V, De Marinis L, Frustaci A, Catalucci D et al. 2009 Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 120 2377-2385. (doi:10.1161/CIRCULATIONAHA.109.879429)
19. Etlinger JD & Goldberg AL 1977 A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. PNAS 74 54-58. (doi:10.1073/pnas.74.1.54)
20. Frias MA, Rebsamen MC, Gerber-Wicht C & Lang U 2007 Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: a role in cardiac hypertrophy. Cardiovascular Research 73 57-65. (doi:10.1016/j.cardiores.2006.09.016)
21. Hedhli N & Depre C 2010 Proteasome inhibitors and cardiac cell growth. Cardiovascular Research 85 321-329. (doi:10.1093/cvr/cvp226)
22. Hiroi Y, Kim HH, Ying H, Furuya F, Huang Z, Simoncini T, Noma K, Ueki K, Nguyen NH, Scanlan TS et al. 2006 Rapid nongenomic actions of thyroid hormone. PNAS 103 14104-14109. (doi:10.1073/pnas.0601600103)
23. Hu LW, Benvenuti LA, Liberti EA, Carneiro-Ramos MS & Barreto-Chaves ML 2003 Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 285 R1473-R1480.
24. Ji H, Zhang Y, Zheng W, Wu Z, Lee S & Sandberg K 2004 Translational regulation of angiotensin type 1a receptor expression and signaling by upstream AUGs in the 50 leader sequence. Journal of Biological Chemistry 279 45322-45328. (doi:10.1074/jbc.M407261200)
25. Kahaly GJ & Dillmann WH 2005 Thyroid hormone action in the heart. Endocrine Reviews 26 704-728. (doi:10.1210/er.2003-0033)
26. Kamegai J, Tamura H, Ishii S, Sugihara H & Wakabayashi I 2001 Thyroid hormones regulate pituitary growth hormone secretagogue receptor gene expression. Journal of Neuroendocrinology 13 275-278. (doi:10.1046/j.1365-2826.2001.00623.x)
27. Kapp LD & Lorsch JR 2004 The molecular mechanics of eukaryotic translation. Annual Review of Biochemistry 73 657-704. (doi:10.1146/annurev.biochem.73.030403.080419)
28. Kim MK, Lee JS & Chung JH 1999 In vivo transcription factor recruitment during thyroid hormone receptor-mediated activation. PNAS 96 10092-10097. (doi:10.1073/pnas.96.18.10092)
29. Kobori H, Ichihara A, Suzuki H, Takenaka T, Miyashita Y, Hayashi M & Saruta T 1997 Role of the renin-angiotensin system in cardiac hypertrophy induced in rats by hyperthyroidism. American Journal of Physiology 273 H593-H599.
30. Krane IM, Spindel ER & Chin WW 1991 Thyroid hormone decreases the stability and the poly(A) tract length of rat thyrotropin b-subunit messenger RNA. Molecular Endocrinology 5 469-475. (doi:10.1210/mend-5-4-469)
31. Krishnamurthi K, Verbalis JG, Zheng W, Wu Z, Clerch LB & Sandberg K 1999 Estrogen regulates angiotensin AT1 receptor expression via cytosolic proteins that bind to the 50 leader sequence of the receptor mRNA. Endocrinology 140 5435-5438. (doi:10.1210/en.140.11.5435)
32. Lee S, Ji H, Wu Z, Zheng W, Hassan A & Sandberg K 2006 Translational regulation of ANG II type 1 receptors in proliferating vascular smooth muscle cells. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 290 R50-R56. (doi:10.1152/ajpregu.00448.2005)
33. Li XC, Hopfer U & Zhuo JL 2009 AT1 receptor-mediated uptake of angiotensin II and NHE-3 expression in proximal tubule cells through a microtubule-dependent endocytic pathway. American Journal of Physiology. Renal Physiology 297 F1342 F1352. (doi:10.1152/ajprenal.90734.2008)
34. Liu D & Waxman DJ 2002 Post-transcriptional regulation of hepatic NADPH-cytochrome P450 reductase by thyroid hormone: independent effects on poly(A) tail length and mRNA stability. Molecular Pharmacology 61 1089-1096. (doi:10.1124/mol.61.5.1089)
35. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD & Elton TS 2006 MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. Journal of Biological Chemistry 281 18277-18284. (doi:10.1074/jbc.M601496200)
36. Minamisawa S, Uemura N, Sato Y, Yokoyama U, Yamaguchi T, Inoue K, Nakagome M, Bai Y, Hori H, Shimizu M et al. 2006 Post-transcriptional downregulation of sarcolipin mRNA by triiodothyronine in the atrial myocardium. FEBS Letters 580 2247-2252. (doi:10.1016/j.febslet.2006.03.032)
37. Munroe D & Jacobson A 1990 Tales of poly(A): a review. Gene 91 151-158. (doi:10.1016/0378-1119(90)90082-3)
38. Nickenig G, Michaelsen F, Müller C, Vogel T, Strehlow K & Böhm M 2001 Post-transcriptional regulation of the AT1 receptor mRNA. Identification of the mRNA binding motif and functional characterization. FASEB Journal 15 1490-1492.
39. Nie Y, Han BM, Liu XB, Yang JJ, Wang F, Cong XF & Chen X 2011 Identification of microRNAs involved in hypoxia- and serum deprivation-inducedapoptosis inmesenchymal stemcells. International Journal of Biological Sciences 7 762-768. (doi:10.7150/ijbs.7.762)
40. O'Neal P, Alamdari M, Smith I, Poylin V, Menconi M & Hasselgren PO 2009 Experimental hyperthyroidism in rats increases the expression of the ubiquitin ligases Atrogin-1 and MuRF1 and stimulates multiple proteolytic pathways in skeletal muscle. Journal of Cellular Biochemistry 108 963-973. (doi:10.1002/jcb.22329)
41. Pantos C, Paizis I, Mourouzis I, Moraitis P, Tzeis S, Karamanoli E, Mourouzis C, Karageorgiou H & Cokkinos DV 2005 Blockade of angiotensin II type 1 receptor diminishes cardiac hypertrophy, but does not abolish thyroxin-induced preconditioning. Hormone and Metabolic Research 37 500-504. (doi:10.1055/s-2005-870317)
42. Pantos C, Mourouzis I, Xinaris C, Papadopoulou-Daifoti Z & Cokkinos D 2008 Thyroid hormone and cardiac metamorphosis: potential therapeutic implications. Pharmacology and Therapeutics 118 277-294. (doi:10.1016/j.pharmthera.2008.02.011)
43. Plasterk RH 2006 Micro RNAs in animal development. Cell 124 877-881. (doi:10.1016/j.cell.2006.02.030)
44. Poddar R, Paul S, Chaudhury S & Sarkar PK 1996 Regulation of actin and tubulin gene expression by thyroid hormone during rat brain development. Brain Research. Molecular Brain Research 35 111-118. (doi:10.1016/0169-328X(95)00189-Y)
45. Psarra AM, Solakidi S & Sekeris CE 2006 The mitochondrion as a primary site of action of steroid and thyroid hormones: presence and action of steroid and thyroid hormone receptors in mitochondria of animal cells. Molecular and Cellular Endocrinology 246 21-33. (doi:10.1016/j.mce.2005.11.025)
46. Ribeiro RC, Apriletti JW, West BL, Wagner RL, Fletterick RJ, Schaufele F & Baxter JD 1995 The molecular biology of thyroid hormone action. Annals of the New York Academy of Sciences 758 366-389. (doi:10.1111/j.1749-6632.1995.tb24843.x)
47. Ross J 1995 mRNA stability in mammalian cells. Microbiological Reviews 59 423-450.
48. Sachs A 1990 The role of poly(A) in the translation and stability of mRNA. Current Opinion in Cell Biology 2 1092-1098. (doi:10.1016/0955-0674(90)90161-7)
49. Salles FJ, Richards WG & Strickland S 1999 Assaying the polyadenylation state of mRNAs. Methods 17 38-45. (doi:10.1006/meth.1998.0705)
50. Schlossarek S & Carrier L 2011 The ubiquitin-proteasome system in cardiomyopathies. Current Opinion in Cardiology 26 190-195. (doi:10.1097/HCO.0b013e32834598fe)
51. Serrano-Nascimento C, Calil-Silveira J & Nunes MT 2010 Posttranscriptional regulation of sodium-iodide symporter mRNA expression in the rat thyroid gland by acute iodide administration. American Journal of Physiology. Cell Physiology 298 C893-C899. (doi:10.1152/ajpcell.00224.2009)
52. Shannon JM, Pan T, Edeen KE & Nielsen LD 1998 Influence of the cytoskeleton on surfactant protein gene expression in cultured rat alveolar type II cells. American Journal of Physiology 274 L87-L96.
53. Siegrist-Kaiser CA, Juge-Aubry C, Tranter MP, Ekenbarger DM & Leonard JL 1990 Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel, extranuclear action of thyroid hormone. Journal of Biological Chemistry 265 5296-5302.
54. Silva F, Giannocco G, Santos MF & Nunes MT 2006 Thyroid hormone induction of actin polymerization in somatotrophs of hypothyroid rats: potential repercussions in growth hormone synthesis and secretion. Endocrinology 147 5777-5785. (doi:10.1210/en.2006-0110)
55. 3 acutely increases GH mRNA translation rate and GH secretion in hypothyroid rats. Molecular and Cellular Endocrinology 317 1-7. (doi:10.1016/j.mce.2009.12.005)
56. Singer RH 1992 The cytoskeleton and mRNA localization. Current Opinion in Cell Biology 4 15-19. (doi:10.1016/0955-0674(92)90053-F)
57. Staton JM & Leedman PJ 1998 Posttranscriptional regulation of thyrotropin b-subunit messenger ribonucleic acid by thyroid hormone in murine thyrotrope tumor cells: a conserved mechanism across species. Endocrinology 139 1093-1100. (doi:10.1210/en.139.3.1093)
58. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD & Glass DJ 2004 The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular Cell 14 395-403. (doi:10.1016/S1097-2765(04)00211-4)
59. Su H & Wang X 2010 The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovascular Research 85 253-262. (doi:10.1093/cvr/cvp287)
60. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A et al. 2007 MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116 258-267. (doi:10.1161/CIRCULATIONAHA.107.687947)
61. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S et al. 2008 MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456 980-984. (doi:10.1038/nature07511)
62. 3 action on Akt pathway in human pancreatic insulinoma cells. Journal of Cellular Biochemistry 106 835-848. (doi:10.1002/jcb.22045)
63. Vlahos CJ, McDowell SA & Clerk A 2003 Kinases as therapeutic targets for heart failure. Nature Reviews. Drug Discovery 2 99-113. (doi:10.1038/nrd1009)
64. Wang N, Zhou Z, Liao X & Zhang T 2009 Role of microRNAs in cardiac hypertrophy and heart failure. IUBMB Life 61 566-571. (doi:10.1002/iub.204)
65. Wang WCH, Juan AH, Panebra A & Liggett SB 2011 MicroRNA let-7 establishes expression of b2-adrenergic receptors and dynamically down-regulates agonist-promoted down-regulation. PNAS 108 6246-6251. (doi:10.1073/pnas.1101439108)
66. Willis MS, Townley-Tilson WHD, Kang EY, Homeister JW & Patterson C 2010 Sent to destroy: the ubiquitin-proteasome system regulates cell signaling and protein quality control in cardiovascular development and disease. Circulation Research 106 463-478. (doi:10.1161/CIRCRESAHA.109.208801)
67. Xing Y, Lv A, Wang L & Yan X 2012 The combination of angiotensin II and 5-azacytidine promotes cardiomyocyte differentiation of rat bone marrow mesenchymal stem cells. Molecular and Cellular Biochemistry 360 279-287. (doi:10.1007/s11010-011-1067-z)